1 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, doi:10.1016/j.cell.2011.02.013 (2011).
2 Bonora, M. et al. ATP synthesis and storage. Purinergic Signal 8, 343-357, doi:10.1007/s11302-012-9305-8 (2012).
3 Mueckler, M. et al. Sequence and structure of a human glucose transporter. Science 229, 941-945, doi:10.1126/science.3839598 (1985).
4 Fothergill-Gilmore, L. A. & Michels, P. A. Evolution of glycolysis. Prog Biophys Mol Biol 59, 105-235, doi:10.1016/0079-6107(93)90001-z (1993).
5 Krebs, H. A., Ruffo, A., Johnson, M., Eggleton, L. V. & Hems, R. Oxidative phosphorylation. Biochem J 54, 107-116, doi:10.1042/bj0540107 (1953).
6 Lagunas, R., Dominguez, C., Busturia, A. & Sáez, M. J. Mechanisms of appearance of the Pasteur effect in Saccharomyces cerevisiae: inactivation of sugar transport systems. J Bacteriol 152, 19-25 (1982).
7 Kresge, N., Simoni, R. D. & Hill, R. L. Otto Fritz Meyerhof and the elucidation of the glycolytic pathway. J Biol Chem 280, e3 (2005).
8 Brooks, G. A. Bioenergetics of exercising humans. Compr Physiol 2, 537- 562, doi:10.1002/cphy.c110007 (2012).
9 Warburg, O., Wind, F. & Negelein, E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol 8, 519-530, doi:10.1085/jgp.8.6.519 (1927).
10 Warburg, O. On the origin of cancer cells. Science 123, 309-314, doi:10.1126/science.123.3191.309 (1956).
11 Hsu, P. P. & Sabatini, D. M. Cancer cell metabolism: Warburg and beyond. Cell 134, 703-707, doi:10.1016/j.cell.2008.08.021 (2008).
12 Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11, 325-337, doi:10.1038/nrc3038 (2011).
13 Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033, doi:10.1126/science.1160809 (2009).
14 Pfeiffer, T., Schuster, S. & Bonhoeffer, S. Cooperation and competition in the evolution of ATP-producing pathways. Science 292, 504-507, doi:10.1126/science.1058079 (2001).
15 Hamanaka, R. B. & Chandel, N. S. Targeting glucose metabolism for cancer therapy. J Exp Med 209, 211-215, doi:10.1084/jem.20120162 (2012).
16 de Bari, L. & Atlante, A. Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming. Cell Mol Life Sci 75, 2763-2776, doi:10.1007/s00018-018-2831-y (2018).
17 Sun, S., Li, H., Chen, J. & Qian, Q. Lactic Acid: No Longer an Inert and End-Product of Glycolysis. Physiology (Bethesda) 32, 453-463, doi:10.1152/physiol.00016.2017 (2017).
18 Goyal, M. S., Hawrylycz, M., Miller, J. A., Snyder, A. Z. & Raichle, M. E. Aerobic glycolysis in the human brain is associated with development and neotenous gene expression. Cell Metab 19, 49-57, doi:10.1016/j.cmet.2013.11.020 (2014).
19 Gordon, G. R., Choi, H. B., Rungta, R. L., Ellis-Davies, G. C. & MacVicar, B. A. Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456, 745-749, doi:10.1038/nature07525 (2008).
20 Hirschhaeuser, F., Sattler, U. G. & Mueller-Klieser, W. Lactate: a metabolic key player in cancer. Cancer Res 71, 6921-6925, doi:10.1158/0008- 5472.CAN-11-1457 (2011).
21 Doherty, J. R. & Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 123, 3685-3692, doi:10.1172/jci69741 (2013).
22 Curry, J. M. et al. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle 12, 1371-1384, doi:10.4161/cc.24092 (2013).
23 de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A. & Manzo-Merino, J. Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front Oncol 9, 1143, doi:10.3389/fonc.2019.01143 (2019).
24 Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118, 3930-3942, doi:10.1172/JCI36843 (2008).
25 Martinez-Outschoorn, U. E. et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9, 3256-3276, doi:10.4161/cc.9.16.12553 (2010).
26 Brooks, G. A. The lactate shuttle during exercise and recovery. Med Sci Sports Exerc 18, 360-368, doi:10.1249/00005768-198606000-00019 (1986).
27 Brooks, G. A. Lactate production under fully aerobic conditions: the lactate shuttle during rest and exercise. Fed Proc 45, 2924-2929 (1986).
28 Brooks, G. A. Lactate shuttles in nature. Biochem Soc Trans 30, 258-264, doi:10.1042/ (2002).
29 Brooks, G. A. Cell-cell and intracellular lactate shuttles. J Physiol 587, 5591-5600, doi:10.1113/jphysiol.2009.178350 (2009).
30 Mason, S. Lactate Shuttles in Neuroenergetics-Homeostasis, Allostasis and Beyond. Front Neurosci 11, 43, doi:10.3389/fnins.2017.00043 (2017).
31 Cai, T. Q. et al. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun 377, 987-991, doi:10.1016/j.bbrc.2008.10.088 (2008).
32 Ge, H. et al. Elucidation of signaling and functional activities of an orphan GPCR, GPR81. J Lipid Res 49, 797-803, doi:10.1194/jlr.M700513-JLR200 (2008).
33 Liu, C. et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 284, 2811-2822, doi:10.1074/jbc.M806409200 (2009).
34 Kuei, C. et al. Study of GPR81, the lactate receptor, from distant species identifies residues and motifs critical for GPR81 functions. Mol Pharmacol 80, 848-858, doi:10.1124/mol.111.074500 (2011).
35 Lauritzen, K. H. et al. Lactate receptor sites link neurotransmission, neurovascular coupling, and brain energy metabolism. Cereb Cortex 24, 2784-2795, doi:10.1093/cercor/bht136 (2014).
36 Ahmed, K. et al. An autocrine lactate loop mediates insulin-dependent inhibition of lipolysis through GPR81. Cell Metab 11, 311-319, doi:10.1016/j.cmet.2010.02.012 (2010).
37 Lee, Y. J. et al. G-protein-coupled receptor 81 promotes a malignant phenotype in breast cancer through angiogenic factor secretion. Oncotarget 7, 70898-70911, doi:10.18632/oncotarget.12286 (2016).
38 Roland, C. L. et al. Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Res 74, 5301-5310, doi:10.1158/0008- 5472.Can-14-0319 (2014).
39 Kitajima, S. et al. The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene 36, 5145-5157, doi:10.1038/onc.2017.124 (2017).
40 Lampugnani, M. G. Cell migration into a wounded area in vitro. Methods Mol Biol 96, 177-182, doi:10.1385/1-59259-258-9:177 (1999).
41 Shaw, L. M. Tumor cell invasion assays. Methods Mol Biol 294, 97-105, doi:10.1385/1-59259-860-9:097 (2005).
42 Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10, 1523, doi:10.1038/s41467-019-09234-6 (2019).
43 Hiraga, T. et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res 72, 4238-4249, doi:10.1158/0008-5472.Can-11-3061 (2012).
44 Wakabayashi, H. et al. Decreased sensory nerve excitation and bone pain associated with mouse Lewis lung cancer in TRPV1-deficient mice. J Bone Miner Metab 36, 274-285, doi:10.1007/s00774-017-0842-7 (2018).
45 Hiasa, M. et al. Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3. Cancer Res 77, 1283-1295, doi:10.1158/0008-5472.can-15-3545 (2017).
46 Coleman, R. E. et al. Bone metastases. Nat Rev Dis Primers 6, 83, doi:10.1038/s41572-020-00216-3 (2020).
47 Okui, T. et al. The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone. J Bone Oncol 26, 100330, doi:10.1016/j.jbo.2020.100330 (2021).
48 Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature reviews. Cancer 2, 584-593, doi:10.1038/nrc867 (2002).
49 Yoneda, T. & Hiraga, T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328, 679-687, doi:10.1016/j.bbrc.2004.11.070 (2005).
50 Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nature reviews. Cancer 11, 411-425, doi:10.1038/nrc3055 (2011).
51 Suva, L. J., Washam, C., Nicholas, R. W. & Griffin, R. J. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7, 208- 218, doi:10.1038/nrendo.2010.227 (2011).
52 Ren, G., Esposito, M. & Kang, Y. Bone metastasis and the metastatic niche. J Mol Med (Berl) 93, 1203-1212, doi:10.1007/s00109-015-1329-4 (2015).
53 Ell, B. & Kang, Y. SnapShot: Bone Metastasis. Cell 151, 690-690.e691, doi:10.1016/j.cell.2012.10.005 (2012).
54 Insel, P. A., Zhang, L., Murray, F., Yokouchi, H. & Zambon, A. C. Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf) 204, 277-287, doi:10.1111/j.1748-1716.2011.02273.x (2012).
55 Stork, P. J. & Schmitt, J. M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12, 258-266, doi:10.1016/s0962-8924(02)02294-8 (2002).
56 Bhola, N. E. & Grandis, J. R. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 13, 1857-1865, doi:10.2741/2805 (2008).
57 Castoria, G. et al. Integrating signals between cAMP and MAPK pathways in breast cancer. Front Biosci 13, 1318-1327, doi:10.2741/2764 (2008).
58 Cho-Chung, Y. S., Clair, T., Bodwin, J. S. & Berghoffer, B. Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine. Science 214, 77-79, doi:10.1126/science.6269181 (1981).
59 Chen, J. et al. Expression of Q227L-galphas in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci U S A 95, 2648- 2652, doi:10.1073/pnas.95.5.2648 (1998).
60 Kim, S. N. et al. 8-Cl-cAMP induces cell cycle-specific apoptosis in human cancer cells. Int J Cancer 93, 33-41, doi:10.1002/ijc.1308 (2001).
61 Santore, T. A., Chen, Y., Smit, M. J. & Iyengar, R. Adenovirus-directed expression of Q227L-G alpha(s) inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice. Proc Natl Acad Sci U S A 99, 1671-1676, doi:10.1073/pnas.032661999 (2002).
62 Burdyga, A. et al. cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: effects of PKA and EPAC. Biochim Biophys Acta 1833, 2664-2672, doi:10.1016/j.bbamcr.2013.06.011 (2013).
63 Dong, H., Claffey, K. P., Brocke, S. & Epstein, P. M. Inhibition of breast cancer cell migration by activation of cAMP signaling. Breast Cancer Res Treat 152, 17-28, doi:10.1007/s10549-015-3445-9 (2015).
64 Pattabiraman, D. R. et al. Activation of PKA leads to mesenchymal-toepithelial transition and loss of tumor-initiating ability. Science 351, aad3680, doi:10.1126/science.aad3680 (2016).
65 Wu, Y. et al. Lactate enhanced the effect of parathyroid hormone on osteoblast differentiation via GPR81-PKC-Akt signaling. Biochem Biophys Res Commun 503, 737-743, doi:10.1016/j.bbrc.2018.06.069 (2018).
66 Chen, F. et al. Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol 21, 498-510, doi:10.1038/s41556-019- 0299-0 (2019).
67 Bovenzi, C. D. et al. Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis. Biomed Res Int 2015, 242437, doi:10.1155/2015/242437 (2015).
68 Zhu, J. et al. Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients. PLoS One 9, e87904, doi:10.1371/journal.pone.0087904 (2014).
69 Simões-Sousa, S. et al. Prognostic significance of monocarboxylate transporter expression in oral cavity tumors. Cell Cycle 15, 1865-1873, doi:10.1080/15384101.2016.1188239 (2016).
70 Tamura, D., Hiraga, T., Myoui, A., Yoshikawa, H. & Yoneda, T. Cadherin11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol 33, 17-24 (2008).
71 Tao, J., Erez, A. & Lee, B. One NOTCH Further: Jagged 1 in Bone Metastasis. Cancer Cell 19, 159-161, doi:10.1016/j.ccr.2011.01.043 (2011).
72 Shen, Z. et al. Inhibition of G protein-coupled receptor 81 (GPR81) protects against ischemic brain injury. CNS Neurosci Ther 21, 271-279, doi:10.1111/cns.12362 (2015).
73 Beloueche-Babari, M. et al. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy. Cancer Res 77, 5913- 5924, doi:10.1158/0008-5472.CAN-16-2686 (2017)
論文の公開元へ
